Effect of the new 75-mg orodispersible film of sildenafil on erection and sexual quality of life: insights from an observational study

Author:

Sansone Andrea1,Frangione Valeria2,Lanzarotti Arturo2,Cocci Andrea3,Ceruti Carlo4,De Sio Marco5,Imbimbo Ciro6,Mirone Vincenzo7,Schips Luigi8,Terrone Carlo9,Jannini Emmanuele A1

Affiliation:

1. University of Rome Tor Vergata Section of Endocrinology and Medical Sexology (ENDOSEX), , Rome, Italy

2. IBSA Institut Biochimique SA, Pambio-Noranco , Switzerland

3. University of Florence IBSA Institut Biochimique SA Section of Urology, Careggi Hospital, , Pambio-Noranco, Florence, Italy

4. University of Turin Division of Urology, , Turin, Italy

5. University “Luigi Vanvitalli” of Naples Urology Unit, , Naples, Italy

6. University “Federico II” of Naples Andrology Unit, , Naples, Italy

7. University “Federico II” of Naples Urology Unit, , Naples, Italy

8. University of Chieti Department of Urology, SS Annunziata Hospital, , Chieti, Italy

9. University of Genova. Department of Urology, IRCCS Ospedale Policlinico San Martino, , Genova, Italy

Abstract

AbstractBackgroundThe newly devised orodispersible film (ODF) of sildenafil is the first phosphodiesterase type 5 inhibitor (PDE5i) available in a 75-mg dose. This intermediate dose and the particular properties of the ODF formulation can improve the clinical management of erectile dysfunction (ED) patients.AimWe investigated the effects of the sildenafil ODF 75-mg dose on both sexual quality of life and erectile function based on the results from an observational study in daily practice in Italy.MethodsThis study was a post hoc analysis of results from an observational, real-life study carried out in ED patients at 6 treatment centers in Italy. All subjects were asked to take the prescribed dose of sildenafil ODF at inclusion (visit 1) and to return for a control visit (visit 2) to confirm or adapt the prescribed dose after a minimum of 4 weeks. An end of study control visit (visit 3) was performed after additional 4 weeks.OutcomesErectile function, assessed by the International Index of Erectile Function–Erectile Function (IIEF-EF) domain; sexual quality of life, measured using the sexual quality of life instrument for men (SQoL-M).ResultsAmong the 36 subjects initially recruited for the 75-mg dose, 5 patients dropped out of the study (2 at visit 2 and 3 at visit 3), none of whom due to treatment inefficacy or serious adverse events. At visit 2, the mean (SD) IIEF-EF scores significantly increased (∆ = 7.97 [4.71], P < 0.0001) as SQoL-M scores also did (∆ = 10.76 [10.46], P < 0.0001). At visit 3, IIEF-EF and SQoL-M scores were still significantly improved compared to baseline (∆ = 10.64 [7.01], P < 0.0001, and ∆ = 18.15 [12.32], P < 0.0001, respectively). By ANCOVA, we found no significant effects for age, BMI, previous use of PDE5i, presence of metabolic comorbidities, or smoking habits on study outcomes at both visits 2 and 3.Clinical implicationThe new 75-mg ODF sildenafil formulation is a safe and effective treatment for ED, significantly improving both erectile function and sexual quality of life in patients undergoing treatment.Strengths and limitationsThis is the first study assessing the efficacy of the sildenafil ODF 75-mg dose in a real-life setting. However, the small sample size, possible underlying cultural factors, and limited availability of clinically relevant data may have affected the reliability of our results.ConclusionThe use of the 75 mg ODF formulation for sildenafil represents an effective and safe novel treatment option for ED patients.

Funder

Italian Ministry of University PRIN

Publisher

Oxford University Press (OUP)

Subject

Behavioral Neuroscience,Urology,Dermatology,Reproductive Medicine,Endocrinology,Endocrinology, Diabetes and Metabolism,Psychiatry and Mental health

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3